Physician profile
Joseph E Saucedo
NPI 1164485140
$2,690.08
in general payments reported to CMS, 2019-2025
22 companies · $85.90 in 2025
The $85.90 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $515 · 2021: $812 · 2022: $426 · 2023: $189 · 2024: $173 · 2025: $85.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $447.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $965.59 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $712.87 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $168.28 | 2021-2024 | Mounjaro, Zepbound, Emgality |
| Amarin Pharma, INC. | $116.60 | 2020-2021 | |
| Pfizer INC. | $116.09 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $106.87 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $98.43 | 2020-2022 | |
| Horizon Therapeutics Plc | $41.22 | 2019-2020 | |
| Biogen, INC. | $37.57 | 2020-2021 | |
| Allergan, INC. | $36.03 | 2019-2020 | |
| Exact Sciences Corporation | $35.58 | 2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $29.79 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.76 | 2022-2023 | |
| Amgen INC. | $28.23 | 2020 | |
| Abbvie INC. | $27.86 | 2022-2023 | Synthroid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $26.80 | 2021 | |
| Linus Health, INC. | $26.02 | 2023 | |
| Tris Pharma INC | $21.61 | 2023 | Dyanavel Xr |
| Abbott Laboratories | $17.50 | 2023 | Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $17.26 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.04 | 2021 | |
| Glaxosmithkline, LLC. | $15.08 | 2024 | Trelegy Ellipta, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Saucedo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.